Parexel Highlights Real-World Oncology Research and Expands CRO Evidence Capabilities

• Parexel is expanding its focus on real-world oncology research as part of its broader CRO strategy to support clinical development and market access.

• The company highlighted new capabilities designed to integrate real-world evidence (RWE) into oncology development programs, regulatory planning, and long-term evidence generation.

Parexel highlighted its growing investment in real-world oncology research, reinforcing the role of real-world evidence (RWE) within its contract research organization (CRO) services for cancer drug development. The company presented new initiatives focused on integrating clinical trial data with real-world datasets to support oncology development strategies. 

The expanded approach is designed to help sponsors generate evidence across the full development lifecycle, including clinical development, regulatory submissions, payer engagement, and post-approval research. According to Parexel, combining clinical trial data with real-world evidence can provide additional insights into treatment effectiveness, patient outcomes, and long-term safety. 

From a CRO perspective, the strategy reflects increasing demand for integrated evidence-generation models in oncology, where sponsors are seeking broader datasets to support precision medicine programs and reimbursement decisions. Parexel’s oncology teams work across clinical development, regulatory strategy, genomics, and biostatistics, supporting studies from early-phase research through post-marketing evidence generation. 

The company also emphasized the growing role of advanced analytics and AI-enabled technologies in managing large-scale oncology datasets. These tools are being used to support study design, patient identification, site selection, and evidence generation, helping sponsors accelerate development timelines while maintaining data quality and regulatory compliance. 

“Our RWE experts work with clients to explore the impact of a therapy and/or disease in a real-world setting, generating data that will support your value proposition to regulators, payers, physicians, and patients.” 

Official Parexel Statement